Johnson & Johnson Reports Q1 Revenue Growth Amid Sharp Net Income Decline

Johnson & Johnson (JNJ) has released its financial results for the first quarter of 2026, revealing a notable divergence between top-line expansion and net profitability. While the healthcare giant successfully grew its revenue base, GAAP earnings plummeted, suggesting the impact of non-recurring items or shifting cost structures. Revenue for the period rose 9.9% to $24.06 billion, up from $21.89 billion in the same quarter last year. However, this growth did not translate to the bottom line on a GAAP basis. Net income dropped to $5.23 billion, or $2.14 per share, compared to $10.99 billion, or $4.54 per share, in the prior year's first quarter. To provide a clearer view of operational performance, the company reported adjusted earnings of $6.61 billion, or $2.70 per share, excluding specific items. This adjusted figure offers a more tempered view of the company's current profitability trajectory. Looking ahead, Johnson & Johnson provided full-year earnings per share (EPS) guidance in the range of $11.45 to $11.65. Market participants will likely focus on the company's ability to convert its revenue growth into sustainable net income throughout the remainder of the fiscal year.